

Hal K Berman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1208798/publications.pdf>

Version: 2024-02-01

18
papers

1,222
citations

1040056

9
h-index

1058476

14
g-index

18
all docs

18
docs citations

18
times ranked

3022
citing authors

#	ARTICLE	IF	CITATIONS
1	All is not lost: learning from 9p21 loss in cancer. Trends in Immunology, 2022, 43, 379-390.	6.8	12
2	Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumab. , 2022, 10, e004378.		4
3	External validation of the VICex gene-expression signature (GES) as a novel predictive biomarker for immune checkpoint treatment (ICT).. Journal of Clinical Oncology, 2022, 40, 2510-2510.	1.6	1
4	Applications of Circulating Tumor DNA in a Cohort of Phase I Solid Tumor Patients Treated With Immunotherapy. JNCI Cancer Spectrum, 2021, 5, pkaa122.	2.9	12
5	Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity. Nature Communications, 2021, 12, 5137.	12.8	63
6	Tumor cell expression of B7-H4 correlates with higher frequencies of tumor-infiltrating APCs and higher CXCL17 expression in human epithelial ovarian cancer. OncoImmunology, 2019, 8, e1665460.	4.6	27
7	Breast specimen handling and reporting in the post-neoadjuvant setting: challenges and advances. Journal of Clinical Pathology, 2019, 72, 120-132.	2.0	20
8	Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer. Breast Cancer Research and Treatment, 2018, 168, 159-168.	2.5	27
9	Phase II (INSPIRE) trial of pembrolizumab (pembro) with serial immune and genomic profiling in patients (pts) with metastatic triple negative breast cancer (mTNBC).. Journal of Clinical Oncology, 2018, 36, 1094-1094.	1.6	2
10	Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. Genome Medicine, 2016, 8, 109.	8.2	211
11	Germline and somatic homologous recombination gene mutations in high-grade serous ovarian cancer and clinical outcome.. Journal of Clinical Oncology, 2016, 34, 5579-5579.	1.6	0
12	Glutathione and Thioredoxin Antioxidant Pathways Synergize to Drive Cancer Initiation and Progression. Cancer Cell, 2015, 27, 211-222.	16.8	748
13	B7-H4 Expression by Nonhematopoietic Cells in the Tumor Microenvironment Promotes Antitumor Immunity. Cancer Immunology Research, 2015, 3, 184-195.	3.4	36
14	Association between pretreatment neutrophil to lymphocyte ratio (NLR) and complete pathological response (pCR) in breast cancer patients treated with neoadjuvant chemotherapy (NACT).. Journal of Clinical Oncology, 2015, 33, e11588-e11588.	1.6	2
15	Somatic mutation profiling of advanced breast and ovarian cancers according to germline BRCA1/2 mutation status.. Journal of Clinical Oncology, 2015, 33, 1532-1532.	1.6	0
16	Retinoblastoma pathway deregulatory mechanisms determine clinical outcome in high-grade serous ovarian carcinoma. Modern Pathology, 2014, 27, 991-1001.	5.5	41
17	Princess Margaret Cancer Centre (PMCC) Integrated Molecular Profiling in Advanced Cancers Trial (IMPACT) using genotyping and targeted next-generation sequencing (NGS).. Journal of Clinical Oncology, 2013, 31, 11002-11002.	1.6	16
18	Impact of endocrine therapy in early-stage breast cancer on time to locoregional recurrence.. Journal of Clinical Oncology, 2013, 31, 64-64.	1.6	0